Lipoprotein(a) Test: The Inherited Heart Risk Most Doctors Skip

Quick answer: A lipoprotein a test (written clinically as a lipoprotein(a) test) measures Lp(a), a genetically determined cholesterol particle that raises your risk of heart attack, stroke, and aortic valve disease independently of LDL or HDL. Normal is generally below 30 mg/dL (or below 75 nmol/L in molar units); one in five Americans carries levels high enough to matter clinically. You only need to test once in your life because Lp(a) is roughly 80 to 90 percent set by your DNA and does not change meaningfully with diet or most medications.

What exactly is Lp(a) and why does it matter more than most cholesterol markers?

Lp(a) is an LDL-like particle with an extra protein called apolipoprotein(a) glued onto it by a disulfide bond. That extra protein makes Lp(a) uniquely dangerous: it carries oxidized phospholipids that trigger arterial inflammation, it interferes with clot dissolution (fibrinolysis), and it appears to drive calcification of the aortic valve directly. Standard lipid panels do not report Lp(a). Your cardiologist can have completely normal LDL, HDL, and triglycerides and still carry a lipoprotein(a) level that doubles their lifetime heart attack risk.

The clinical community has been slow to adopt routine Lp(a) testing largely because, until very recently, there were no approved drugs that specifically targeted it. That is changing. In late 2024 and 2025, PCSK9-inhibitor data and RNA-based therapies in phase 3 trials moved Lp(a)-lowering from theoretical to near-clinical reality. That shift is the main reason the European Society of Cardiology, the National Lipid Association, and most major cardiology guidelines now recommend measuring Lp(a) at least once in every adult.

If you are reviewing the best biomarkers to test for long-term cardiovascular risk, Lp(a) belongs on that list before ApoB for people with a family history of early heart disease.

What is the lipoprotein(a) normal range?

Below 30 mg/dL is widely considered normal; above 50 mg/dL is the threshold most guidelines call “high risk”; above 100 mg/dL is severe and carries risk comparable to familial hypercholesterolemia. In molar units (which some labs prefer), the equivalent cutoffs are roughly below 75 nmol/L (normal) and above 125 nmol/L (high risk).

Lp(a) Level (mg/dL)	Lp(a) Level (nmol/L)	Risk Category	Approximate Population %
Below 30	Below 75	Normal / low risk	~60%
30 to 49	75 to 124	Borderline	~20%
50 to 99	125 to 249	High risk	~15%
100 and above	250 and above	Very high / FH-equivalent	~5%

One critical nuance: labs report Lp(a) in either mg/dL or nmol/L, and there is no universal conversion factor because the size of apolipoprotein(a) varies between individuals. A result of 60 mg/dL at one lab is not numerically comparable to 60 nmol/L at another. Always note which unit your result uses and compare future tests in the same units at the same lab if possible.

Population data consistently shows that people of South Asian, Black African, and West African descent carry higher average Lp(a) levels than those of European ancestry, with South Asians averaging roughly 30 to 40 percent higher concentrations. Risk thresholds do not change by ethnicity, but knowing your background helps contextualize a borderline result.

What is an optimal Lp(a) versus a merely normal one?

Lab reference ranges tell you what is common, not what is ideal. The standard cutoff of 30 mg/dL is where population risk starts climbing, but the lowest event rates in large cohort data sit closer to the bottom of the range, in the single digits and teens. If your result comes back at 25 mg/dL you are technically normal, yet you carry slightly more baseline risk than someone at 8 mg/dL. This gradient matters most when you already have other risk factors stacking on top. Do not treat 29 mg/dL as a clean pass and 31 mg/dL as a crisis. Risk rises continuously across the range, and the 30 and 50 mg/dL lines are convenient guideposts, not biological switches.

There is also a floor effect worth knowing. Very low Lp(a), under roughly 10 mg/dL, is common and carries no known downside. Unlike markers where both extremes signal trouble, there is no such thing as dangerously low Lp(a). If your number is near zero, that is the result you want, and no clinician will ask you to raise it.

Why is high Lp(a) almost always genetic?

Lp(a) concentration is controlled almost entirely by variants in the LPA gene on chromosome 6, particularly the number of “kringle IV type 2” repeats in apolipoprotein(a). Fewer repeats mean larger isoforms but paradoxically lower plasma levels; more repeats mean smaller isoforms and, often, higher plasma concentrations. This inheritance pattern is autosomal codominant, meaning one copy of a high-risk LPA variant is enough to elevate your Lp(a). If one parent has high Lp(a), each child has roughly a 50 percent chance of inheriting it.

Diet, exercise, statins, fibrates, and niacin change Lp(a) very little, if at all. PCSK9 inhibitors (evolocumab, alirocumab) lower Lp(a) by roughly 20 to 30 percent, which is meaningful but rarely enough to bring very high levels into the normal range. This is why the test matters: identifying a high Lp(a) triggers cascade screening of first-degree relatives, not a prescription change to your current statin.

The genetic nature of Lp(a) also explains the “test once” recommendation. Barring a new drug that dramatically lowers it, your Lp(a) at age 30 is essentially your Lp(a) at age 70. There is no clinical reason to retest every year the way you would track LDL or HbA1c.

Who should get a lipoprotein(a) test?

The short answer: every adult, at least once. But the people who should push hardest for it are those with family history of early heart attack (before age 55 in men, before 65 in women), personal history of heart attack or stroke with otherwise normal LDL, calcific aortic valve disease without clear risk factors, or any first-degree relative who has already been found to have high Lp(a).

Clinicians who specialize in preventive cardiology and lipidology have a standing joke: the patients who need Lp(a) testing most are the ones whose primary care physician told them their cholesterol looks fine. High Lp(a) produces no visible symptoms, does not show up on a standard lipid panel, and contributes to atherosclerosis the same way high LDL does but through a partially different mechanism. A 45-year-old marathon runner with low LDL and no obvious risk factors can carry an Lp(a) of 180 nmol/L and have the plaque burden of someone 20 years older.

Children of a parent with confirmed high Lp(a) are worth testing around age 8 to 10, earlier than most cardiovascular biomarkers, because lifetime exposure to elevated Lp(a) appears to matter. This is an area where pediatric lipid specialists diverge from general pediatricians, but the trend is toward earlier identification.

A realistic scenario: the fit 48-year-old with a family surprise

Consider a 48-year-old who exercises five days a week, eats well, has an LDL of 95 mg/dL, and has never smoked. On paper his standard lipid panel looks unremarkable, and three different physicians have told him his cholesterol is fine. His father had a heart attack at 52. Because of that single fact he requests an Lp(a) test, and it comes back at 165 nmol/L. Nothing about his lifestyle caused that number and nothing about his lifestyle will lower it, but the result changes his plan. His clinician sets an LDL target below 70 mg/dL, adds a coronary artery calcium scan, and tests his two adult siblings. One sibling turns out to carry the same elevated Lp(a) and had no idea. That cascade, one test triggering family screening and a tighter risk plan, is exactly what Lp(a) testing is designed to catch, and it is invisible to every standard panel he had done before.

How much does a lipoprotein(a) test cost?

Cash-pay Lp(a) tests at commercial labs run roughly $29 to $75 at Quest Diagnostics and Labcorp through online ordering portals, and $40 to $90 at direct-to-consumer services. Walk-in lab pricing is typically higher than online-ordered pricing at the same facility. HSA and FSA dollars are accepted at most commercial labs for a physician-ordered test.

Where You Order	Typical Cash Price	Notes
Quest / Labcorp online portal	$29 to $55	Draw at a patient service center; results in 2 to 4 days
Direct-to-consumer panel services	$40 to $75	Often bundled with lipid panel; result in 3 to 5 days
Primary care physician order	Copay or coinsurance	Insurance coverage inconsistent; verify before ordering
Comprehensive baseline panels	$150 to $400 (Lp(a) included)	Lp(a) bundled alongside full metabolic, CBC, hormones
Cardiologist referral	Specialist copay	Usually covered if billing supports medical necessity

Insurance coverage for Lp(a) is uneven. Medicare Part B covers it when the ordering provider documents medical necessity tied to cardiovascular risk assessment or a family history flag. Commercial payers vary widely. United Healthcare and Aetna cover it with a cardiac risk diagnosis code in most plans; Blue Cross Blue Shield coverage depends on the regional plan. Many plans still classify it as preventive screening without a specific ICD-10 code, which can result in patient cost-sharing even when ordered by a cardiologist. If you are ordered an Lp(a) test, ask your provider to confirm the diagnosis code they are using before the blood draw.

If you are getting blood drawn anyway for a full baseline, it is almost always smarter to capture Lp(a) at the same visit rather than schedule a second phlebotomy. Here is how a comprehensive full-body panel compares in terms of what you get for the draw.

How is the lipoprotein(a) test performed?

Lp(a) is measured from a standard venous blood draw, typically 3 to 5 mL in a serum separator tube (the gold-capped or red-capped tube). Fasting is not required for Lp(a) specifically, unlike LDL or triglycerides, because Lp(a) concentrations are not meaningfully affected by recent food intake. The lab separates serum, then measures Lp(a) via immunoturbidimetry or ELISA using antibodies to apolipoprotein(a).

One technical point worth knowing: the accuracy of Lp(a) measurement depends heavily on which antibody assay the lab uses. Some older immunoturbidimetry assays cross-react with different apolipoprotein(a) isoform sizes in ways that produce systematically higher or lower readings. Reference labs like Quest and Labcorp have calibrated their assays against World Health Organization reference standards, so their mg/dL results are generally comparable. If you test at a small regional hospital lab that uses a different manufacturer’s kit, the number may not align perfectly. Clinicians who manage Lp(a) seriously tend to send patients to Quest or Labcorp for this reason.

Results typically return within one to three business days. They do not require interpretation alongside a reference range table the way TSH or ferritin do; the number itself, compared to the 50 mg/dL threshold, tells most of the story.

What happens if your Lp(a) comes back high?

A high Lp(a) does not require an immediate medication change. It does require a conversation with a clinician about recalibrating your overall cardiovascular risk estimate and thinking about whether to be more aggressive with the risk factors you can modify, specifically LDL, blood pressure, blood sugar, smoking, and inflammation.

The practical implications of a result above 50 mg/dL typically include: lowering your LDL target to below 70 mg/dL (or below 55 mg/dL if you also have any other cardiovascular risk factor), considering aspirin therapy depending on your bleeding risk and age, and possibly adding coronary artery calcium (CAC) scoring to get a structural assessment of whether the Lp(a) has already done damage. A CAC score of zero in someone with very high Lp(a) is genuinely reassuring; a CAC score above 100 in the same person means aggressive risk factor management is justified now, not eventually.

For people with Lp(a) above 100 mg/dL, referral to a lipid specialist or preventive cardiology clinic is reasonable. This is the group most likely to benefit from the Lp(a)-lowering drugs currently in late-stage trials (muvalaplin, pelacarsen, olpasiran), and registering with a clinical trial site while they are still pre-approval is an option some high-Lp(a) patients actively pursue.

A complete blood panel at the same time as your Lp(a) gives your clinician the full metabolic context to risk-stratify you properly, particularly fasting glucose, HbA1c, and hsCRP alongside lipids.

Can you lower lipoprotein(a)?

Meaningfully and reliably: no, not with currently available treatments. This is the most important thing to understand about a high Lp(a) result, and the thing most patients get wrong. Unlike LDL, Lp(a) does not respond to statins, a Mediterranean diet, weight loss, or exercise. Niacin lowers it modestly but niacin is no longer recommended for cardiovascular risk reduction because outcome trials showed no benefit. PCSK9 inhibitors (evolocumab, alirocumab) reduce Lp(a) by 20 to 30 percent, which is real but rarely enough to normalize very elevated levels and not their primary indication.

The honest framing: if your Lp(a) is 90 mg/dL, you cannot eat or exercise it down to 30 mg/dL. What you can do is drive your modifiable risks as low as possible so that the fixed Lp(a) burden has fewer co-conspirators. That means pushing LDL below 70 mg/dL with statins if needed, controlling blood pressure tightly, maintaining a healthy weight, and not smoking.

The therapeutic landscape is shifting. RNA interference drugs (small interfering RNA and antisense oligonucleotides targeting LPA gene expression) are producing 70 to 90 percent Lp(a) reductions in trials. If approved in 2026 or 2027, they will convert a currently unmodifiable risk factor into a treatable one. Identifying your Lp(a) now means you will already know whether you are a candidate when those therapies become available.

Explore the broader set of best biomarkers to test alongside Lp(a) to build a complete cardiovascular risk picture rather than responding to one number in isolation.

How does Lp(a) fit with your other heart markers?

Lp(a) is not meant to be read alone. It is one input into a risk picture that also includes ApoB, LDL cholesterol, blood pressure, fasting glucose or HbA1c, and hsCRP. The reason clinicians pair it with ApoB in particular is that ApoB counts the total number of atherogenic particles in your blood, while Lp(a) tells you whether one specific, inflammation-prone, clot-resistant particle is present in large numbers. High ApoB with high Lp(a) is a worse combination than either alone, because you have both a high particle count and a particularly nasty particle within it.

hsCRP adds the inflammation layer. Because Lp(a) carries oxidized phospholipids that inflame the artery wall, a person with high Lp(a) and high hsCRP is running two engines of arterial damage at once. Coronary artery calcium scoring then tells you whether those engines have already produced structural plaque. The sequence most preventive cardiologists follow is straightforward: measure Lp(a) once to know the fixed risk, track ApoB and LDL over time as the modifiable levers, watch hsCRP as the inflammation gauge, and use a CAC scan to see what has actually accumulated in the arteries.

This is why capturing Lp(a) inside a full panel rather than as an isolated test tends to pay off. The single number is only actionable in context. A 42-year-old with Lp(a) of 140 nmol/L, ApoB of 60 mg/dL, hsCRP of 0.4 mg/L, and a CAC score of zero is in a very different position from a 42-year-old with the same Lp(a) but ApoB of 130 mg/dL, hsCRP of 3 mg/L, and a CAC score of 90, even though their Lp(a) is identical.

What people get wrong about the lipoprotein(a) test

The most common mistake is assuming that because Lp(a) is genetic and currently unmodifiable, there is no point in testing. That reasoning is backwards. Knowing your Lp(a) changes clinical behavior: it lowers LDL targets, changes imaging recommendations, triggers family screening, and changes how aggressively your clinician manages your other risk factors. Ignorance of your Lp(a) is not neutral; it is a decision to not act on information that would have changed management.

The second mistake is testing repeatedly. Lp(a) is stable over a lifetime. Retesting every year is a waste of money and adds nothing. Test once, record the result, done.

The third mistake is conflating Lp(a) with LDL because both are lipid particles. They are structurally different, they respond differently to treatment, and a normal LDL does not imply a normal Lp(a). A standard lipid panel simply does not measure Lp(a). If you want to know your Lp(a), you have to specifically request it or order it separately.

A less obvious error: comparing results across labs without noting the units. Seeing 60 on one report and 60 on another does not mean the values are the same if one is in mg/dL and the other is in nmol/L. The molar mass of Lp(a) varies by isoform, so there is no single conversion factor. Your clinician should note the units and the lab when they record the result.

Testing an albumin test alongside Lp(a) is worth considering for older adults, since hypoalbuminemia and high Lp(a) together signal accelerated vascular aging via different but complementary mechanisms.

FAQ

Is a lipoprotein(a) test the same as a regular cholesterol test?

No. A standard lipid panel measures total cholesterol, LDL, HDL, and triglycerides. Lp(a) is not included. You must specifically request an Lp(a) test or order it separately. The two tests require the same blood draw but analyze different proteins.

How do I get a lipoprotein(a) test without a doctor’s order?

In most US states you can order an Lp(a) test directly through Quest Diagnostics, Labcorp, or direct-to-consumer lab services without a physician’s prescription. You pay cash, visit the nearest patient service center, and receive results online, typically within two to four days. Prices typically run $29 to $75 depending on the service.

Does fasting matter before a lipoprotein(a) test?

No. Unlike LDL and triglycerides, Lp(a) concentrations are not affected by recent meals. You can eat and drink normally before the blood draw. If you are testing Lp(a) alongside a full lipid panel, fast for that panel’s sake, not for the Lp(a) specifically.

What does an Lp(a) result of 50 mg/dL mean in practice?

The 50 mg/dL threshold is where most guidelines draw the line between borderline and high cardiovascular risk. At 50 mg/dL, your clinician should factor Lp(a) into your overall risk calculation, consider setting a lower LDL target, and potentially discuss whether coronary artery calcium scoring is warranted. It does not automatically mean you need new medication, but it means the risk management conversation changes.

Can inflammation or illness temporarily raise Lp(a)?

Yes. Lp(a) is an acute-phase reactant, meaning severe illness, surgery, or systemic inflammation can temporarily elevate it by 20 to 30 percent. This is why it is worth noting if you were sick or recovering from a procedure when you tested. Most clinicians recommend waiting at least four to six weeks after a major illness or surgery before measuring Lp(a) for baseline purposes.

Is high Lp(a) related to stroke risk as well as heart attack risk?

Yes. Elevated Lp(a) is associated with ischemic stroke risk, primarily through its pro-thrombotic and pro-inflammatory properties. The association is strongest for stroke in younger adults (under 55) without other obvious risk factors. Interestingly, hemorrhagic stroke risk does not appear to be elevated and may be slightly lower with high Lp(a), possibly because of the same fibrinolysis interference that makes arterial clots more dangerous.

Do children need a lipoprotein(a) test?

If a parent has confirmed high Lp(a), pediatric lipid specialists often recommend testing children around ages 8 to 10. The rationale is that early identification allows for aggressive management of all modifiable cardiovascular risk factors from childhood onward, reducing the cumulative exposure to combined Lp(a) plus LDL plus lifestyle risk. General pediatric guidelines have not universally adopted this, so it typically requires a referral to a pediatric lipidologist.

Can the adiponectin test or other metabolic markers predict who will have high Lp(a)?

No reliable metabolic predictor exists for high Lp(a) because it is genetically determined rather than metabolically regulated. An adiponectin test reflects insulin sensitivity and adipose tissue inflammation but has no meaningful correlation with Lp(a) levels. The only way to know your Lp(a) is to measure it directly. There is no metabolic proxy.

How often should I retest my Lp(a)?

For most people, once is enough for life. The exceptions are narrow: if your first result was drawn during a serious illness, surgery recovery, or pregnancy, repeat it once you are back to baseline, since Lp(a) can rise temporarily as an acute-phase reactant. The other reason to retest is if you start one of the new Lp(a)-lowering therapies now in late-stage trials, in which case you would measure it to confirm the drug is working. Outside those situations, annual Lp(a) testing adds cost and no information.

Does menopause or hormone therapy change Lp(a)?

Lp(a) tends to rise modestly after menopause, and oral estrogen therapy can lower it somewhat, but neither shift is large enough to change the test’s core message or to be used as a treatment for high Lp(a). If you tested before menopause and again after, do not be alarmed by a moderate increase. The genetic setpoint still dominates, and the clinical thresholds do not move.

Can I have a heart attack with normal Lp(a)?

Absolutely. Lp(a) is one risk factor among several, not a master switch. Plenty of heart attacks happen in people with low Lp(a) but high LDL, high blood pressure, diabetes, or a heavy smoking history. A normal Lp(a) removes one inherited risk factor from your profile, it does not make you immune. This is why Lp(a) is meant to sharpen an overall risk estimate rather than replace it.

Does the vitamin A test have anything to do with lipoprotein(a)?

They are completely unrelated clinically. A vitamin A test measures retinol for nutritional status; lipoprotein(a) is a cardiovascular risk marker. The two sometimes appear on comprehensive panels together, but there is no known functional relationship between retinol status and Lp(a) concentrations in otherwise healthy adults.